Advertisement

L'Endocrinologo

, Volume 19, Issue 1, pp 21–25 | Cite as

I recettori della somatostatina nella terapia dei tumori neuroendocrini del tratto gastroenteropancreatico

  • Andrea Lania
  • Elisabetta Lavezzi
  • Eleonora Vitali
  • Carlo Carnaghi
Rassegna
  • 38 Downloads

Sommario

I tumori neuroendocrini (NET) sono un gruppo eterogeneo di neoplasie che originano dal sistema neuroendocrino diffuso e che si caratterizzano per un relativo ridotto tasso di crescita e per la possibile secrezione di ormoni o di peptidi vasoattivi. I NET, la cui prevalenza è significativamente aumentata negli ultimi decenni, rappresentano il 2% di tutte le neoplasie del polmone e la seconda più frequente forma di neoplasia maligna del trattato gastroenterico, seconda sola al carcinoma del colon. Quella chirurgica è la terapia di scelta nei pazienti con NET ben localizzati. Tuttavia, il 40% dei pazienti con NET si presenta alla diagnosi con malattia metastatica che richiede, pertanto, ulteriori terapie sia locoregionali che sistemiche. A tale proposito, negli ultimi anni sono state approvate terapie a bersaglio molecolare (quali everolimus e sunitinib) per l’utilizzo nei pazienti con NET in progressione. Si è inoltre osservato un progressivo ampliamento del ruolo degli analoghi della somatostatina nel trattamento dei NET. Se gli analoghi della somatostatina trovavano inizialmente spazio nel controllo della sintomatologia legata alla secrezione di ormoni o peptidi vasoattivi (come nel caso della sindrome da carcinoide), studi recenti hanno dimostrato come tali farmaci siano efficaci nel controllo della progressione di malattia nel caso di NET non funzionanti avanzati.

Parole chiave

Analoghi della somatostatina Tumori neuroendocrini Terapia radiorecettoriale 

Notes

Conflitto di interesse

Gli autori Andrea Lania, Elisabetta Lavezzi, Eleonora Vitali e Carlo Carnaghi dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_396_MOESM1_ESM.doc (27 kb)
(DOC 27 kB)
40619_2018_396_MOESM2_ESM.doc (26 kb)
(DOC 26 kB)

Bibliografia

  1. 1.
    Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocr Rev 12:450–482 CrossRefPubMedGoogle Scholar
  2. 2.
    Papotti M, Bongiovanni M, Volante M et al. (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440(5):461–475 CrossRefPubMedGoogle Scholar
  3. 3.
    Körner M, Waser B, Reubi JC (2015) Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Neuroendocrinology 101:45–57 CrossRefPubMedGoogle Scholar
  4. 4.
    Öberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23(12):R551–R566 CrossRefPubMedGoogle Scholar
  5. 5.
    Cives M, Strosberg J (2015) The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs 75(8):847–858 CrossRefPubMedGoogle Scholar
  6. 6.
    Toumpanakis C, Caplin ME (2013) Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol 40(1):56–68 CrossRefPubMedGoogle Scholar
  7. 7.
    Pyronnet S, Bousquet C, Najib S et al. (2008) Antitumor effects of somatostatin. Mol Cell Endocrinol 286:230–237 CrossRefPubMedGoogle Scholar
  8. 8.
    Bousquet C, Lasfargues C, Chalabi M et al. (2012) Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab 97(3):727–737 CrossRefPubMedGoogle Scholar
  9. 9.
    Vitali E, Cambiaghi V, Spada A et al. (2015) cAMP effects in neuroendocrine tumors: the role of Epac and PKA in cell proliferation and adhesion. Exp Cell Res 339(2):241–251 CrossRefPubMedGoogle Scholar
  10. 10.
    Ferrante E, Pellegrini C, Bondioni S et al. (2006) Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr-Relat Cancer 13:955–962 CrossRefPubMedGoogle Scholar
  11. 11.
    Murray RD, Kim K, Ren SG et al. (2004) Central and peripheral actions of somatostatin on the growth hormone—IGF-I axis. J Clin Invest 114:349–356 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Vitali E, Cambiaghi V, Zerbi A et al. (2016) Filamin-A is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours. Endocr Relat Cancer 23(3):181–190 CrossRefPubMedGoogle Scholar
  13. 13.
    Oberg K (2013) The genetics of neuroendocrine tumors. Semin Oncol 40:37–44 CrossRefPubMedGoogle Scholar
  14. 14.
    Kohout TA, Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9–18 CrossRefPubMedGoogle Scholar
  15. 15.
    Gurevich VV, Gurevich EV (2006) The structural basis of arrestin mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465–502 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Luttrell LM, Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305–330 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu Q, Bee MS, Schonbrunn A (2009) Site specificity of agonist and second messenger-activated kinases for somatostatin receptor subtype 2A (SSTR2A) phosphorylation. Mol Pharmacol 76:68–80 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cambiaghi V, Vitali E, Morone D et al. (2017) Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine 56(1):146–157 CrossRefPubMedGoogle Scholar
  19. 19.
    Dimitriadis GK, Weickert MO, Randeva HS et al. (2016) Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 23(9):R423–R436 CrossRefPubMedGoogle Scholar
  20. 20.
    Rinke A, Müller H-H, Schade-Brittinger C et al. (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:4656–4663 CrossRefPubMedGoogle Scholar
  21. 21.
    Caplin ME, Pavel M, Ćwikła JB et al. (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233 CrossRefPubMedGoogle Scholar
  22. 22.
    Sampedro-Núñez M, Luque RM, Ramos-Levi AM et al. (2016) Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 7(6):6593–6608 CrossRefPubMedGoogle Scholar
  23. 23.
    Luque RM, Ibáñez-Costa A, Neto LV et al. (2015) Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett 359(2):299–306 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Andrea Lania
    • 1
    • 2
  • Elisabetta Lavezzi
    • 1
  • Eleonora Vitali
    • 3
  • Carlo Carnaghi
    • 4
  1. 1.U.O. di Endocrinologia e Andrologia MedicaIstituto Clinico HumanitasRozzanoItalia
  2. 2.Dipartimento di Scienze BiomedicheHumanitas UniversityRozzanoItalia
  3. 3.Laboratorio di Endocrinologia Cellulare e MolecolareFondazione Humanitas per la RicercaRozzanoItalia
  4. 4.U.O. OncologiaIstituto Clinico HumanitasRozzanoItalia

Personalised recommendations